See the DrugPatentWatch profile for cosentyx

According to the prescribing information for Cosentyx (secukinumab), the recommended dose for the treatment of moderate to severe plaque psoriasis is 150 mg. [1] This dose is administered as an injection every 4 weeks.

The prescribing information also states that the recommended dose for the treatment of active psoriatic arthritis is 150 mg. [2] This dose is also administered as an injection every 4 weeks.

It's worth noting that the dose of Cosentyx may need to be adjusted based on the patient's response to treatment. [3] Additionally, the prescribing information recommends that the dose be administered every 4 weeks, but it does not specify the exact number of milligrams administered per dose.

DrugPatentWatch.com provides information on the patent status of Cosentyx, but it does not provide information on the specific dose of the medication. [4]

Sources:

[1] Cosentyx Prescribing Information. (2020). Retrieved from <https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/cosentyx-pi.pdf>

[2] Cosentyx Prescribing Information. (2020). Retrieved from <https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/cosentyx-pi.pdf>

[3] Cosentyx Prescribing Information. (2020). Retrieved from <https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/cosentyx-pi.pdf>

[4] DrugPatentWatch.com. (n.d.). Secukinumab (Cosentyx). Retrieved from <https://www.drugpatentwatch.com/drugs/c/cosentyx>